Small molecule · developed by Tempest Therapeutics
TPST-1495 is an orally administered agent studied in solid tumors, including colorectal cancer, non-small cell lung cancer, head and neck squamous cell carcinoma, urothelial carcinoma, endometrial cancer and gastric or gastroesophageal junction adenocarcinoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04344795 | Phase 1 | Solid Tumor | Completed | TPST |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Colorectal CancerEndometrial CancerGastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaNon Small Cell Lung CancerSolid TumorSolid Tumors With PIK3Ca MutationSquamous Cell Carcinoma of Head and NeckUrothelial Carcinoma
Updated Nov 1, 2026. Something wrong or missing? Report it on the TPST page.
See TPST's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TPST catalysts and pipeline →